Interact with experts and peers.

Recent Posts

10 of 113 Shown
  • CROI 2018: Randomized Trial Data on the Risk of IRIS When Starting INSTI-Based ART

    Chloe Orkin MBChB, FRCP, MD - 4/17/2018
    Should patients with advanced HIV disease be started on INSTI-based regimens?
  • How New Data From IAS 2017 May Inform Dual-Therapy Options for HIV Treatment

    Daniel R. Kuritzkes MD - 9/12/2017 3 comments / Last Comment: 10/16/2017
    Should dual-therapy ART be considered in the first-line setting for some patients?
  • How New Data From IAS 2017 May Inform Use of ART in Patients With Cardiovascular or Bone Comorbidities

    Daniel R. Kuritzkes MD - 9/11/2017 3 comments / Last Comment: 11/12/2017
    Can switching ART improve cardiovascular or bone health?
  • IAS 2017 Data Shed Light on the Potential Use of Investigational ART Coformulations

    Daniel R. Kuritzkes MD - 9/11/2017 2 comments / Last Comment: 10/16/2017
    How do phase III data on bictegravir and doravirine affect the potential future HIV treatment landscape? Here’s my take.
  • IAS 2017: How New Data on First-line Dual Therapy and Second-Line ART Are Changing My Practice

    Babafemi Taiwo MBBS - 8/23/2017 3 comments / Last Comment: 9/18/2017
    Data presented at the latest IAS meeting highlight how new ART approaches are shifting HIV treatment paradigms. Here is my take.
  • IAS 2017: A Preview of Key Data to Be Presented in Paris

    Anton L. Pozniak MD, FRCP - 7/17/2017 3 comments / Last Comment: 7/21/2017
    Here is my take on the most anticipated studies that will be presented in Paris this year.
  • Weighing Boosted vs Unboosted Options for a Patient Who Requires Treatment Prior to Availability of Resistance Data

    Eric S. Daar MD - 6/21/2017 2 comments / Last Comment: 9/12/2017
    For a newly diagnosed patient with an OI and pending resistance test results, when and with what would you recommend initiating ART?
  • Optimizing ART for a Patient With PI Intolerance and a History of Resistance and Nonadherence

    Eric S. Daar MD - 6/21/2017 1 comment / Last Comment: 6/22/2017
    Would you switch a virologically suppressed patient who is experiencing PI toxicity to a PI-sparing regimen if they had a history of nonadherence and resistance?
  • Weighing Boosted vs Unboosted Options for a Patient With Comorbidities Who Desires an STR

    Eric S. Daar MD - 6/21/2017 1 comment / Last Comment: 9/12/2017
    What is the optimal ART regimen for a patient with CKD and CVD who desires an STR?
  • Choosing Statins for Patients With Dyslipidemia and Elevated CVD Risk

    David A. Wohl MD - 6/1/2017 2 comments / Last Comment: 8/16/2017
    Which statins should be avoided in patients receiving boosted ART regimens?
10 of 113 Shown
Show 10 More